Fleseriu M, Pivonello R, Elenkova A, et al. - Through the SONICS (a phase 3, multicentre, open-label, non-randomized, single-arm study) trial of adults (≥ 18 years) with authenticated Cushing syndrome and a mean 24-h urinary free cortisol of at least 1·5 times the upper limit of normal, researchers examined the efficiency and safety of levoketoconazole in individuals with endogenous Cushing syndrome. A total of 201 people were screened and 94 were recruited and received at least one dose of study medication between July 30, 2014, and June 30, 2017. In urinary free cortisol, with an agreeable safety and tolerability profile, twice-daily oral levoketoconazole treatment resulted in maintained betterments. Moreover, for the medical treatment of Cushing syndrome, levoketoconazole might represent a beneficial therapeutic choice.